SIGA Technologies, Inc.
31 East 62nd Street
New York, NY 10065
United States
212 672 9100
https://www.siga.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 45
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Daniel J. Luckshire | Executive VP, CFO & Secretary | 1.42M | 無 | 1971 |
| Dr. Dennis E. Hruby Ph.D. | Executive VP & Chief Scientific Officer | 1.41M | 無 | 1952 |
| Dr. Jay K. Varma M.D. | Executive VP, Chief Medical Officer & Director | 1.04M | 無 | 1972 |
| Dr. Diem Nguyen M.B.A., Ph.D. | CEO & Director | 無 | 無 | 1972 |
| Ms. Tove C. Bolken | Senior VP of Operations & Chief Supply Chain Officer | 無 | 無 | 無 |
| Mr. Herb Vloedman | Senior VP & Chief Information Officer | 無 | 無 | 無 |
| Mr. Lawrence R. Miller Esq., J.D. | General Counsel | 無 | 無 | 1968 |
截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
公司管治
截至 2024年5月1日 止，SIGA Technologies, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：8；董事會：9；股東權利：2；現金賠償：8。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
